Our top pick for
Enzo Biochem Inc is a diagnostics & research business based in the US. Enzo Biochem shares (ENZ) are listed on the NYSE and all prices are listed in US Dollars.
|Latest market close||$3.31|
|52-week range||$1.80 - $4.15|
|50-day moving average||$3.64|
|200-day moving average||$3.28|
|Wall St. target price||$5.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.03|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||-12.43%|
|1 month (2021-09-23)||-8.56%|
|3 months (2021-07-23)||5.75%|
|6 months (2021-04-23)||1.53%|
|1 year (2020-10-23)||57.62%|
|2 years (2019-10-23)||3.44%|
|3 years (2018-10-23)||3.36|
|5 years (2016-10-21)||5.93|
Valuing Enzo Biochem stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Enzo Biochem's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Enzo Biochem's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 140x. In other words, Enzo Biochem shares trade at around 140x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Enzo Biochem's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2.4 million.
The EBITDA is a measure of a Enzo Biochem's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$112.4 million|
|Gross profit TTM||$23.8 million|
|Return on assets TTM||-0.09%|
|Return on equity TTM||2.01%|
|Market capitalisation||$183.2 million|
TTM: trailing 12 months
There are currently 623,668 Enzo Biochem shares held short by investors – that's known as Enzo Biochem's "short interest". This figure is 6% up from 588,216 last month.
There are a few different ways that this level of interest in shorting Enzo Biochem shares can be evaluated.
Enzo Biochem's "short interest ratio" (SIR) is the quantity of Enzo Biochem shares currently shorted divided by the average quantity of Enzo Biochem shares traded daily (recently around 79651.085568327). Enzo Biochem's SIR currently stands at 7.83. In other words for every 100,000 Enzo Biochem shares traded daily on the market, roughly 7830 shares are currently held short.
However Enzo Biochem's short interest can also be evaluated against the total number of Enzo Biochem shares, or, against the total number of tradable Enzo Biochem shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Enzo Biochem's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Enzo Biochem shares in existence, roughly 10 shares are currently held short) or 0.0202% of the tradable shares (for every 100,000 tradable Enzo Biochem shares, roughly 20 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Enzo Biochem.
Find out more about how you can short Enzo Biochem stock.
We're not expecting Enzo Biochem to pay a dividend over the next 12 months.
Enzo Biochem's shares were split on a 105:100 basis on 20 October 2004. So if you had owned 100 shares the day before before the split, the next day you'd have owned 105 shares. This wouldn't directly have changed the overall worth of your Enzo Biochem shares – just the quantity. However, indirectly, the new 4.8% lower share price could have impacted the market appetite for Enzo Biochem shares which in turn could have impacted Enzo Biochem's share price.
Over the last 12 months, Enzo Biochem's shares have ranged in value from as little as $1.8 up to $4.15. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Enzo Biochem's is 0.8418. This would suggest that Enzo Biochem's shares are less volatile than average (for this exchange).
Enzo Biochem, Inc. , an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.